"The miCAR platform allows us to move beyond gene editing into an ability to silence up to six different genes," Kili told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. "What this does is makes incredibly powerful cells in a very simple, easy way, which has a much lower cost of goods but a much higher ability to have quality cells."
Kili, who is chair of the ISCT 2022 Business Models & Investment Subcommittee and co-chair of the annual meeting, said Antion Biosciences is starting out with a proof-of-concept involving the miCAR platform's use in creating allogeneic T cells with a first indication in T cell malignancies. The company will then progress to solid tumors.
Watch the video below to learn more.